IT Dept Detects Rs 400-Crore Black Income After Raids On Hyderabad-Based Pharma Group

Hyderabad : The Income Tax Department has detected “unaccounted” income of about Rs 400 crore after raids on a major pharmaceutical group based in Hyderabad, the Central Board of Direct Taxes (CBDT) said on Monday.

The searches were carried out on February 24 at around 20 locations spread across five states.

The CBDT said the pharmaceutical group is engaged in the business of manufacturing of intermediates, active pharmaceutical ingredients (APIs) and formulations, and majority of its products are exported to European countries and the USA.

“The search has led to unearthing of evidence relating to unaccounted income of around Rs 400 crore, out of which the assessee group has admitted an additional income of Rs 350 crore,” the CBDT claimed in a statement.

It added that Rs 1.66 crore cash was also seized during the operation.

“Incriminating evidence in the form of digital media, pen drives, documents, etc. have been found and seized,” the CBDT said.

The statement said digital evidences were gathered from SAP-ERP software.

“Issues relating to purchases made from bogus and non-existent entities, artificial inflation of certain heads of expenditure, alongwith suppression of receipts relating to by-product sale were detected.

“Evidence of on-money payment for purchase of lands was also found,” it alleged.

Multiple other legal issues were also identified such as personal expenses being booked in the company’s books and land purchased by related concerns or individuals below government value, the CBDT said.

  • Related Posts

    Commissioner FDA reviews enforcement measures

    Srinagar: Commissioner, Food & Drugs Administration (FDA), Jammu & Kashmir, Khalid Jahangir on Thursday held an introductory meeting with senior officers and field functionaries of Drug and Food Wing of the…

    Karnataka High Court stays FSSAI advisory banning use of Ashwagandha leaves in health supplements

    Karnataka High Court Ashwagandha ruling offers interim relief to supplement makers challenging the FSSAI advisory on Ashwagandha extracts. The Karnataka High Court has stayed an advisory issued by the Food…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Commissioner FDA reviews enforcement measures

    Commissioner FDA reviews enforcement measures

    Karnataka High Court stays FSSAI advisory banning use of Ashwagandha leaves in health supplements

    Karnataka High Court stays FSSAI advisory banning use of Ashwagandha leaves in health supplements

    Roche Pharma launches Tecentriq® SC, India’s first subcutaneous immunotherapy for lung cancer

    Roche Pharma launches Tecentriq® SC, India’s first subcutaneous immunotherapy for lung cancer

    CDSCO tighten drug quality oversight as substandard and spurious medicine cases rise in five years

    CDSCO tighten drug quality oversight as substandard and spurious medicine cases rise in five years

    Piramal Pharma Gets 3 USFDA Observations at US Facility

    Piramal Pharma Gets 3 USFDA Observations at US Facility

    Eli Lilly pauses Indian obesity awareness campaign after regulatory notices

    Eli Lilly pauses Indian obesity awareness campaign after regulatory notices